The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
File Type:
PDFItem Type:
Journal ArticleDate:
2016Author:
Access:
openAccessCitation:
Breslin S, O'Driscoll L, The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance., Oncotarget, 7, 29, 2016, 45745 - 45756Download Item:
Abstract:
Solid tumours naturally grow in 3D wherein the spatial arrangement of cells
affects how they interact with each other. This suggests that 3D cell culture may
mimic the natural in vivo setting better than traditional monolayer (2D) cell culture,
where cells are grown attached to plastic. Here, using HER2-positive breast cancer
cell lines as models (BT474, HCC1954, EFM192A), the effects of culturing cells in
3D using the poly-HEMA method compared to 2D cultures were assessed in terms
of cellular viability, response/resistance to anti-cancer drugs, protein expression
and enzyme activity. Scanning electron microscopy showed the morphology of cells
in 3D to be substantially different to those cultured in 2D. Cell viability in 3D cells
was substantially lower than that of cells in 2D cultures, while 3D cultures were
more resistant to the effects of HER-targeted (neratinib) and classical chemotherapy
(docetaxel) drugs. Expression of proteins involved in cell survival, transporters
associated with drug resistance and drug targets were increased in 3D cultures.
Finally, activity of drug metabolising enzyme CYP3A4 was substantially increased in 3D
compared to 2D cultures. Together this data indicates that the biological information
represented by 3D and 2D cell cultures is substantially different i.e. 3D cell cultures
demonstrate higher innate resistance to anti-cancer drugs compared to 2D cultures,
which may be facilitated by the altered receptor proteins, drug transporters and
metabolising enzyme activity. This highlights the importance of considering 3D in
addition to 2D culture methods in pre-clinical studies of both newer targeted and
more traditional anti-cancer drugs.
Sponsor
Grant Number
Health Research Board (HRB)
HRA_POR/2013/342
Higher Education Authority (HEA)
Cycle 5
Irish Cancer Society
CCRC13GAL
Author's Homepage:
http://people.tcd.ie/lodriscDescription:
PUBLISHED
Author: O'Driscoll, Lorraine
Type of material:
Journal ArticleSeries/Report no:
Oncotarget7
29
Availability:
Full text availableSubject (TCD):
Cancer , BREAST CANCER , Drug resistanceDOI:
10.18632/oncotarget.9935Metadata
Show full item recordLicences: